{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T04:54:49Z","timestamp":1794891289860,"version":"4.9.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100010711","name":"Sy\u00f6p\u00e4s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007417","name":"Paulon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007417","id-type":"DOI","asserted-by":"publisher"}]},{"name":"University of Helsinki Doctoral Program in Biomedicine"},{"DOI":"10.13039\/501100003125","name":"Suomen Kulttuurirahasto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003125","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009067","name":"K. Albin Johanssons Stiftelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007083","name":"Orionin Tutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003756","name":"Biomedicum Helsinki-s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003756","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"name":"iCAN Digital Precision Cancer Medicine Flagship"},{"DOI":"10.13039\/501100004012","name":"Jane ja Aatos Erkon S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004012","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BJC Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Uterine leiomyosarcomas are rare and aggressive cancers with poor survival. Their non-cancerous counterparts, uterine leiomyomas, are common tumors affecting many women during reproductive years. Distinguishing leiomyosarcomas from leiomyomas remains a diagnostic challenge. This study aimed to identify molecular biomarkers that differentiate leiomyosarcomas from leiomyomas and to assess their prognostic value.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed 3\u2032RNA sequencing data from 51 leiomyosarcomas and 44 leiomyomas with differential gene expression analysis and machine learning to identify diagnostic biomarkers. We utilized immunohistochemistry to validate the findings. We used Kaplan\u2013Meier and Cox regression models to assess disease-specific survival in leiomyosarcoma patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Leiomyosarcomas exhibited significant dysregulation of the retinoblastoma and cell cycle pathways. Clustering based on retinoblastoma pathway genes identified a subset of leiomyosarcomas with a leiomyoma-like expression profile that associated with better survival. Machine learning-based classification identified genes with high predictive accuracy, including genes from the retinoblastoma pathway. Immunohistochemistry validated TOP2A and CDK1 as potential diagnostic biomarkers, and their higher expression was associated with worse survival. Leiomyoma driver alterations were found in 27% of leiomyosarcomas, but these showed no association with survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our results reveal molecular heterogeneity in uterine leiomyosarcomas and provide potential diagnostic and prognostic biomarkers for improved patient management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1038\/s44276-025-00190-x","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T16:09:11Z","timestamp":1761754151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Transcriptome profiling of uterine leiomyosarcomas identifies a leiomyoma-like expression pattern that indicates better survival"],"prefix":"10.1038","volume":"3","author":[{"given":"Sara","family":"Khamaiseh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riitta","family":"Koivisto-Korander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nora","family":"Schreiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esa","family":"Pitk\u00e4nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terhi","family":"Ahvenainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"B\u00fctzow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miika","family":"Mehine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4615-3825","authenticated-orcid":false,"given":"Pia","family":"Vahteristo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"190_CR1","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1002\/ijc.22239","volume":"119","author":"JR Toro","year":"2006","unstructured":"Toro JR, Travis LB, Wu HJ, Zhu K, Fletcher CD, Devesa SS. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978-2001: an analysis of 26,758 cases. Int J Cancer. 2006;119:2922\u201330.","journal-title":"Int J Cancer"},{"key":"190_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.maturitas.2012.01.021","volume":"72","author":"R Koivisto-Korander","year":"2012","unstructured":"Koivisto-Korander R, Martinsen JI, Weiderpass E, Leminen A, Pukkala E. Incidence of uterine leiomyosarcoma and endometrial stromal sarcoma in Nordic countries: results from NORDCAN and NOCCA databases. Maturitas. 2012;72:56\u201360.","journal-title":"Maturitas"},{"key":"190_CR3","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1111\/aogs.12930","volume":"95","author":"M Skorstad","year":"2016","unstructured":"Skorstad M, Kent A, Lieng M. Uterine leiomyosarcoma - incidence, treatment, and the impact of morcellation. A nationwide cohort study. Acta Obstet Gynecol Scand. 2016;95:984\u201390.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"190_CR4","doi-asserted-by":"crossref","unstructured":"Yang Q, Madueke-Laveaux OS, Cun H, Wlodarczyk M, Garcia N, Carvalho KC, et al. Comprehensive review of uterine leiomyosarcoma: pathogenesis, diagnosis, prognosis, and targeted therapy. Cells. 2024;13:1106.","DOI":"10.3390\/cells13131106"},{"key":"190_CR5","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/PAP.0000000000000478","volume":"32","author":"A Momeni-Boroujeni","year":"2025","unstructured":"Momeni-Boroujeni A, Nucci MR, Chapel DB. Risk stratification of uterine smooth muscle tumors: the role of morphology, immunohistochemistry, and molecular testing. Adv Anat Pathol. 2025;32:44\u201356.","journal-title":"Adv Anat Pathol"},{"key":"190_CR6","doi-asserted-by":"publisher","first-page":"103 e1","DOI":"10.1016\/j.ajog.2017.09.014","volume":"218","author":"BL Seagle","year":"2018","unstructured":"Seagle BL, Alexander AL, Strohl AE, Shahabi S. Discussing sarcoma risks during informed consent for nonhysterectomy management of fibroids: an unmet need. Am J Obstet Gynecol. 2018;218:103 e1\u20135.","journal-title":"Am J Obstet Gynecol"},{"key":"190_CR7","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jmig.2014.08.781","volume":"22","author":"EA Pritts","year":"2015","unstructured":"Pritts EA, Parker WH, Brown J, Olive DL. Outcome of occult uterine leiomyosarcoma after surgery for presumed uterine fibroids: a systematic review. J Minim Invasive Gynecol. 2015;22:26\u201333.","journal-title":"J Minim Invasive Gynecol"},{"key":"190_CR8","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1136\/ijgc-2024-005823","volume":"34","author":"I Ray-Coquard","year":"2024","unstructured":"Ray-Coquard I, Casali PG, Croce S, Fennessy FM, Fischerova D, Jones R, et al. ESGO\/EURACAN\/GCIG guidelines for the management of patients with uterine sarcomas. Int J Gynecol Cancer. 2024;34:1499\u2013521.","journal-title":"Int J Gynecol Cancer"},{"key":"190_CR9","doi-asserted-by":"publisher","first-page":"e1005850","DOI":"10.1371\/journal.pgen.1005850","volume":"12","author":"N M\u00e4kinen","year":"2016","unstructured":"M\u00e4kinen N, Aavikko M, Heikkinen T, Taipale M, Taipale J, Koivisto-Korander R, et al. Exome sequencing of uterine leiomyosarcomas identifies frequent mutations in TP53, ATRX, and MED12. PLoS Genet. 2016;12:e1005850.","journal-title":"PLoS Genet"},{"key":"190_CR10","doi-asserted-by":"publisher","first-page":"1230","DOI":"10.1002\/ijc.31129","volume":"142","author":"T Cuppens","year":"2018","unstructured":"Cuppens T, Moisse M, Depreeuw J, Annibali D, Colas E, Gil-Moreno A, et al. Integrated genome analysis of uterine leiomyosarcoma to identify novel driver genes and targetable pathways. Int J Cancer. 2018;142:1230\u201343.","journal-title":"Int J Cancer"},{"key":"190_CR11","doi-asserted-by":"publisher","first-page":"3881","DOI":"10.1158\/1078-0432.CCR-19-3959","volume":"26","author":"ML Hensley","year":"2020","unstructured":"Hensley ML, Chavan SS, Solit DB, Murali R, Soslow R, Chiang S, et al. Genomic landscape of uterine sarcomas defined through prospective clinical sequencing. Clin Cancer Res. 2020;26:3881\u20138.","journal-title":"Clin Cancer Res"},{"key":"190_CR12","doi-asserted-by":"crossref","unstructured":"Choi J, Manzano A, Dong W, Bellone S, Bonazzoli E, Zammataro L, et al. Integrated mutational landscape analysis of uterine leiomyosarcomas. Proc Natl Acad Sci USA. 2021;118:e2025182118.","DOI":"10.1073\/pnas.2025182118"},{"key":"190_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1067\/mob.2003.99","volume":"188","author":"DD Baird","year":"2003","unstructured":"Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol. 2003;188:100\u20137.","journal-title":"Am J Obstet Gynecol"},{"key":"190_CR14","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/1471-0528.14640","volume":"124","author":"EA Stewart","year":"2017","unstructured":"Stewart EA, Cookson CL, Gandolfo RA, Schulze-Rath R. Epidemiology of uterine fibroids: a systematic review. BJOG. 2017;124:1501\u201312.","journal-title":"BJOG"},{"key":"190_CR15","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.fertnstert.2014.06.050","volume":"102","author":"M Mehine","year":"2014","unstructured":"Mehine M, M\u00e4kinen N, Heinonen HR, Aaltonen LA, Vahteristo P. Genomics of uterine leiomyomas: insights from high-throughput sequencing. Fertil Steril. 2014;102:621\u20139.","journal-title":"Fertil Steril"},{"key":"190_CR16","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41586-021-03747-1","volume":"596","author":"DG Berta","year":"2021","unstructured":"Berta DG, Kuisma H, Valimaki N, Raisanen M, Jantti M, Pasanen A, et al. Deficient H2A.Z deposition is associated with genesis of uterine leiomyoma. Nature. 2021;596:398\u2013403.","journal-title":"Nature"},{"key":"190_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-022-00425-3","volume":"11","author":"M Mehine","year":"2022","unstructured":"Mehine M, Ahvenainen T, Khamaiseh S, Harkonen J, Reinikka S, Heikkinen T, et al. A novel uterine leiomyoma subtype exhibits NRF2 activation and mutations in genes associated with neddylation of the Cullin 3-RING E3 ligase. Oncogenesis. 2022;11:52.","journal-title":"Oncogenesis"},{"key":"190_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1002\/gcc.23088","volume":"62","author":"V Jokinen","year":"2023","unstructured":"Jokinen V, Mehine M, Reinikka S, Khamaiseh S, Ahvenainen T, Ayravainen A, et al. 3\u2019RNA and whole-genome sequencing of archival uterine leiomyomas reveal a tumor subtype with chromosomal rearrangements affecting either HMGA2, HMGA1, or PLAG1. Genes Chromosomes Cancer. 2023;62:27\u201338.","journal-title":"Genes Chromosomes Cancer"},{"key":"190_CR19","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1002\/ijc.27424","volume":"131","author":"DN Markowski","year":"2012","unstructured":"Markowski DN, Bartnitzke S, Loning T, Drieschner N, Helmke BM, Bullerdiek J. MED12 mutations in uterine fibroids\u2013their relationship to cytogenetic subgroups. Int J Cancer. 2012;131:1528\u201336.","journal-title":"Int J Cancer"},{"key":"190_CR20","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1126\/science.1208930","volume":"334","author":"N M\u00e4kinen","year":"2011","unstructured":"M\u00e4kinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ, et al. MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science. 2011;334:252\u20135.","journal-title":"Science"},{"key":"190_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-01199-0","volume":"7","author":"HR Heinonen","year":"2017","unstructured":"Heinonen HR, Pasanen A, Heikinheimo O, Tanskanen T, Palin K, Tolvanen J, et al. Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas. Sci Rep. 2017;7:1015.","journal-title":"Sci Rep"},{"key":"190_CR22","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1093\/humrep\/deaa187","volume":"35","author":"A \u00c4yr\u00e4v\u00e4inen","year":"2020","unstructured":"\u00c4yr\u00e4v\u00e4inen A, Pasanen A, Ahvenainen T, Heikkinen T, Pakarinen P, H\u00e4rkki P, et al. Systematic molecular and clinical analysis of uterine leiomyomas from fertile-aged women undergoing myomectomy. Hum Reprod. 2020;35:2237\u201344.","journal-title":"Hum Reprod"},{"key":"190_CR23","doi-asserted-by":"publisher","first-page":"207e1","DOI":"10.1016\/j.ajog.2022.09.024","volume":"228","author":"K Nagai","year":"2023","unstructured":"Nagai K, Asano R, Sekiguchi F, Asai-Sato M, Miyagi Y, Miyagi E. MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists. Am J Obstet Gynecol. 2023;228:207e1\u2013e9.","journal-title":"Am J Obstet Gynecol"},{"key":"190_CR24","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/hmg\/ddac217","volume":"32","author":"\u00c5 Kolterud","year":"2023","unstructured":"Kolterud \u00c5, V\u00e4lim\u00e4ki N, Kuisma H, Patomo J, Ilves ST, M\u00e4kinen N, et al. Molecular subclass of uterine fibroids predicts tumor shrinkage in response to ulipristal acetate. Hum Mol Genet. 2023;32:1063\u201371.","journal-title":"Hum Mol Genet"},{"key":"190_CR25","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/modpathol.2013.243","volume":"27","author":"E Bertsch","year":"2014","unstructured":"Bertsch E, Qiang W, Zhang Q, Espona-Fiedler M, Druschitz S, Liu Y, et al. MED12 and HMGA2 mutations: two independent genetic events in uterine leiomyoma and leiomyosarcoma. Mod Pathol. 2014;27:1144\u201353.","journal-title":"Mod Pathol"},{"key":"190_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-017-0672-1","volume":"16","author":"N M\u00e4kinen","year":"2017","unstructured":"M\u00e4kinen N, K\u00e4mpj\u00e4rvi K, Frizzell N, B\u00fctzow R, Vahteristo P. Characterization of MED12, HMGA2, and FH alterations reveals molecular variability in uterine smooth muscle tumors. Mol Cancer. 2017;16:101.","journal-title":"Mol Cancer"},{"key":"190_CR27","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1097\/PGP.0000000000000918","volume":"42","author":"DB Chapel","year":"2023","unstructured":"Chapel DB, Sharma A, Maccio L, Bragantini E, Zannoni GF, Yuan L, et al. Fumarate hydratase and S-(2-Succinyl)-cysteine immunohistochemistry shows evidence of fumarate hydratase deficiency in 2% of uterine leiomyosarcomas: a cohort study of 348 tumors. Int J Gynecol Pathol. 2023;42:120\u201335.","journal-title":"Int J Gynecol Pathol"},{"key":"190_CR28","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1016\/j.fertnstert.2014.06.040","volume":"102","author":"HR Heinonen","year":"2014","unstructured":"Heinonen HR, Sarvilinna NS, Sj\u00f6berg J, K\u00e4mpj\u00e4rvi K, Pitk\u00e4nen E, Vahteristo P, et al. MED12 mutation frequency in unselected sporadic uterine leiomyomas. Fertil Steril. 2014;102:1137\u201342.","journal-title":"Fertil Steril"},{"key":"190_CR29","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.ejca.2015.04.023","volume":"51","author":"S Croce","year":"2015","unstructured":"Croce S, Chibon F. MED12 and uterine smooth muscle oncogenesis: state of the art and perspectives. Eur J Cancer. 2015;51:1603\u201310.","journal-title":"Eur J Cancer"},{"key":"190_CR30","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1111\/cas.13613","volume":"109","author":"H Tsuyoshi","year":"2018","unstructured":"Tsuyoshi H, Yoshida Y. Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma. Cancer Sci. 2018;109:1743\u201352.","journal-title":"Cancer Sci"},{"key":"190_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s10689-011-9428-z","volume":"10","author":"HJ Lehtonen","year":"2011","unstructured":"Lehtonen HJ. Hereditary leiomyomatosis and renal cell cancer: update on clinical and molecular characteristics. Fam Cancer. 2011;10:397\u2013411.","journal-title":"Fam Cancer"},{"key":"190_CR32","doi-asserted-by":"publisher","first-page":"320 e1","DOI":"10.1016\/j.ajog.2019.05.018","volume":"221","author":"A Mas","year":"2019","unstructured":"Mas A, Alonso R, Garrido-Gomez T, Escorcia P, Montero B, Jimenez-Almazan J, et al. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing. Am J Obstet Gynecol. 2019;221:320 e1\u2013e23.","journal-title":"Am J Obstet Gynecol"},{"key":"190_CR33","doi-asserted-by":"crossref","unstructured":"Machado-Lopez A, Alonso R, Lago V, Jimenez-Almazan J, Garcia M, Monleon J, et al. Integrative genomic and transcriptomic profiling reveals a differential molecular signature in uterine leiomyoma versus leiomyosarcoma. Int J Mol Sci. 2022;23:2190.","DOI":"10.3390\/ijms23042190"},{"key":"190_CR34","doi-asserted-by":"crossref","unstructured":"Mehine, M, Khamaiseh, S, Ahvenainen, T, Heikkinen, T, \u00c4yr\u00e4v\u00e4inen, A, Pakarinen, P, et al. 3\u2019RNA sequencing accurately classifies formalin-fixed paraffin-embedded uterine leiomyomas. Cancers. 2020;12:3839.","DOI":"10.3390\/cancers12123839"},{"key":"190_CR35","unstructured":"Longacre TA, Lim D, Parra-Herran C. Uterine leiomyosarcoma. In: WHO classification of tumours editorial board, editors. Female genital tumours, WHO classification of tumours, 5th edn. Lyon, France: IARC Publications; 2020, pp. 283\u2013285."},{"key":"190_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2164-12-507","volume":"12","author":"MA Kallio","year":"2011","unstructured":"Kallio MA, Tuimala JT, Hupponen T, Klemel\u00e4 P, Gentile M, Scheinin I, et al. Chipster: user-friendly analysis software for microarray and other high-throughput data. BMC Genomics. 2011;12:507.","journal-title":"BMC Genomics"},{"key":"190_CR37","volume":"2","author":"T Wu","year":"2021","unstructured":"Wu T, Hu E, Xu S, Chen M, Guo P, Dai Z, et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data. Innov ((Camb)). 2021;2:100141.","journal-title":"Innov ((Camb))"},{"key":"190_CR38","doi-asserted-by":"publisher","first-page":"W207","DOI":"10.1093\/nar\/gkad347","volume":"51","author":"L Kolberg","year":"2023","unstructured":"Kolberg L, Raudvere U, Kuzmin I, Adler P, Vilo J, Peterson H. g:Profiler-interoperable web service for functional enrichment analysis and gene identifier mapping (2023 update). Nucleic Acids Res. 2023;51:W207\u2013W12.","journal-title":"Nucleic Acids Res"},{"key":"190_CR39","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/path.2932","volume":"225","author":"C Bardella","year":"2011","unstructured":"Bardella C, El-Bahrawy M, Frizzell N, Adam J, Ternette N, Hatipoglu E, et al. Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status. J Pathol. 2011;225:4\u201311.","journal-title":"J Pathol"},{"key":"190_CR40","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1097\/PAS.0000000000001826","volume":"46","author":"T Ahvenainen","year":"2022","unstructured":"Ahvenainen T, Kaukomaa J, K\u00e4mpj\u00e4rvi K, Uimari O, Ahtikoski A, M\u00e4kinen N, et al. Comparison of 2SC, AKR1B10, and FH antibodies as potential biomarkers for FH-deficient uterine leiomyomas. Am J Surg Pathol. 2022;46:537\u201346.","journal-title":"Am J Surg Pathol"},{"key":"190_CR41","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/j.cell.2017.10.014","volume":"171","author":"Cancer Genome Atlas Research Network","year":"2017","unstructured":"Cancer Genome Atlas Research Network. Electronic address, e.d.s.c., Cancer Genome Atlas Research Network. Comprehensive and integrated genomic characterization of adult soft tissue sarcomas. Cell. 2017;171:950\u201365.e28.","journal-title":"Cell"},{"key":"190_CR42","doi-asserted-by":"publisher","first-page":"pl1","DOI":"10.1126\/scisignal.2004088","volume":"6","author":"J Gao","year":"2013","unstructured":"Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.","journal-title":"Sci Signal"},{"key":"190_CR43","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/19396368.2021.1876179","volume":"67","author":"NN Sahly","year":"2021","unstructured":"Sahly NN, Banaganapalli B, Sahly AN, Aligiraigri AH, Nasser KK, Shinawi T, et al. Molecular differential analysis of uterine leiomyomas and leiomyosarcomas through weighted gene network and pathway tracing approaches. Syst Biol Reprod Med. 2021;67:209\u201320.","journal-title":"Syst Biol Reprod Med"},{"key":"190_CR44","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/PGP.0b013e31815ea7f5","volume":"27","author":"L Chen","year":"2008","unstructured":"Chen L, Yang B. Immunohistochemical analysis of p16, p53, and Ki-67 expression in uterine smooth muscle tumors. Int J Gynecol Pathol. 2008;27:326\u201332.","journal-title":"Int J Gynecol Pathol"},{"key":"190_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2022.100084","volume":"36","author":"A Momeni-Boroujeni","year":"2023","unstructured":"Momeni-Boroujeni A, Yousefi E, Balakrishnan R, Riviere S, Kertowidjojo E, Hensley ML, et al. Molecular-based immunohistochemical algorithm for uterine leiomyosarcoma diagnosis. Mod Pathol. 2023;36:100084.","journal-title":"Mod Pathol"},{"key":"190_CR46","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1158\/1078-0432.CCR-11-3058","volume":"18","author":"W Shan","year":"2012","unstructured":"Shan W, Akinfenwa PY, Savannah KB, Kolomeyevskaya N, Laucirica R, Thomas DG, et al. A small-molecule inhibitor targeting the mitotic spindle checkpoint impairs the growth of uterine leiomyosarcoma. Clin Cancer Res. 2012;18:3352\u201365.","journal-title":"Clin Cancer Res"},{"key":"190_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexmp.2019.104284","volume":"110","author":"CL Adams","year":"2019","unstructured":"Adams CL, Dimitrova I, Post MD, Gibson L, Spillman MA, Behbakht K, et al. Identification of a novel diagnostic gene expression signature to discriminate uterine leiomyoma from leiomyosarcoma. Exp Mol Pathol. 2019;110:104284.","journal-title":"Exp Mol Pathol"},{"key":"190_CR48","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1136\/jclinpath-2015-203561","volume":"69","author":"G Baiocchi","year":"2016","unstructured":"Baiocchi G, Poliseli FL, De Brot L, Mantoan H, Schiavon BN, Faloppa CC, et al. TOP2A copy number and TOP2A expression in uterine benign smooth muscle tumours and leiomyosarcoma. J Clin Pathol. 2016;69:884\u20139.","journal-title":"J Clin Pathol"},{"key":"190_CR49","doi-asserted-by":"publisher","DOI":"10.1186\/s12920-019-0645-x","volume":"12","author":"Q Li","year":"2019","unstructured":"Li Q, Zhang L, Jiang J, Zhang Y, Wang X, Zhang Q, et al. CDK1 and CCNB1 as potential diagnostic markers of rhabdomyosarcoma: validation following bioinformatics analysis. BMC Med Genomics. 2019;12:198.","journal-title":"BMC Med Genomics"},{"key":"190_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3568-y","volume":"17","author":"Y An","year":"2017","unstructured":"An Y, Wang S, Li S, Zhang L, Wang D, Wang H, et al. Distinct molecular subtypes of uterine leiomyosarcoma respond differently to chemotherapy treatment. BMC Cancer. 2017;17:639.","journal-title":"BMC Cancer"},{"key":"190_CR51","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1158\/1078-0432.CCR-19-2891","volume":"26","author":"S Croce","year":"2020","unstructured":"Croce S, Lesluyes T, Valle C, M\u2019Hamdi L, Thebault N, Perot G, et al. The Nanocind signature is an independent prognosticator of recurrence and death in uterine leiomyosarcomas. Clin Cancer Res. 2020;26:855\u201361.","journal-title":"Clin Cancer Res"},{"key":"190_CR52","doi-asserted-by":"publisher","first-page":"2260","DOI":"10.1158\/1078-0432.CCR-24-0148","volume":"30","author":"JK Dermawan","year":"2024","unstructured":"Dermawan JK, Chiang S, Singer S, Jadeja B, Hensley ML, Tap WD, et al. Developing novel genomic risk stratification models in soft tissue and uterine leiomyosarcoma. Clin Cancer Res. 2024;30:2260\u201371.","journal-title":"Clin Cancer Res"},{"key":"190_CR53","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-36","volume":"11","author":"MF de Resende","year":"2013","unstructured":"de Resende MF, Vieira S, Chinen LT, Chiappelli F, da Fonseca FP, Guimaraes GC, et al. Prognostication of prostate cancer based on TOP2A protein and gene assessment: TOP2A in prostate cancer. J Transl Med. 2013;11:36.","journal-title":"J Transl Med"},{"key":"190_CR54","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10549-022-06559-7","volume":"193","author":"Y Wu","year":"2022","unstructured":"Wu Y, Han Y, Li Q, Zhang P, Yuan P, Luo Y, et al. Predictive value of topoisomerase II alpha protein for clinicopathological characteristics and prognosis in early breast cancer. Breast Cancer Res Treat. 2022;193:381\u201392.","journal-title":"Breast Cancer Res Treat"},{"key":"190_CR55","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1128443","volume":"13","author":"Q Du","year":"2023","unstructured":"Du Q, Liu W, Mei T, Wang J, Qin T, Huang D. Prognostic and immunological characteristics of CDK1 in lung adenocarcinoma: a systematic analysis. Front Oncol. 2023;13:1128443.","journal-title":"Front Oncol"},{"key":"190_CR56","doi-asserted-by":"crossref","unstructured":"Khamaiseh, S, Koivisto-Korander, R, Ahvenainen, T, B\u00fctzow, R, Mehine, M, Vahteristo, P. Identification of molecular biomarkers differentiating malignant uterine leiomyosarcoma from benign leiomyoma. Cancer Res. 2023:83:Part 1 (Abstract 996).","DOI":"10.1158\/1538-7445.AM2023-996"}],"container-title":["BJC Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00190-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00190-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00190-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T17:11:48Z","timestamp":1761757908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s44276-025-00190-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["190"],"URL":"https:\/\/doi.org\/10.1038\/s44276-025-00190-x","relation":{},"ISSN":["2731-9377"],"issn-type":[{"value":"2731-9377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"3 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The research has been approved by the ethics review board of the Hospital District of Helsinki and Uusimaa, Finland (88\/13\/03\/03\/2015), and carried out in accordance with the Declaration of Helsinki. Tissue samples and clinical data were collected with written informed consent from the patients or with permission from the National Supervisory Authority for Welfare and Health (Valvira; 602\/06.01.03.01\/2016).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"76"}}